Adjuvant therapy versus watch-and-wait post surgery for stage III melanoma: a multicountry retrospective chart review.
Melanoma Manag
; 6(4): MMT33, 2019 Oct 04.
Article
em En
| MEDLINE
| ID: mdl-31871622
ABSTRACT
AIM:
To describe treatment patterns among patients with stage III melanoma who underwent surgical excision in years 2011-2016, and assess outcomes among patients who subsequently received systemic adjuvant therapy versus watch-and-wait.METHODS:
Chart review of 380 patients from 17 melanoma centers in North America, South America and Europe.RESULTS:
Of 129 (34%) patients treated with adjuvant therapy, 85% received interferon α-2b and 56% discontinued treatment (mostly due to adverse events). Relapse-free survival was significantly longer for patients treated with adjuvant therapy versus watch-and-wait (hazard ratio = 0.63; p < 0.05). There was considerable heterogeneity in adjuvant treatment schedules and doses. Similar results were found in patients who received interferon-based adjuvant therapy.CONCLUSION:
Adjuvant therapies with better safety/efficacy profiles will improve clinical outcomes in patients with stage III melanoma.
Texto completo:
1
Bases de dados:
MEDLINE
Idioma:
En
Revista:
Melanoma Manag
Ano de publicação:
2019
Tipo de documento:
Article
País de afiliação:
Alemanha